-
1
-
-
0036711606
-
Part I: Chemotherapy for epithelial ovarian cancer-treatment at first diagnosis
-
Harries M Gore M. Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. Lancet Oncol 2002 3 529 36.
-
(2002)
Lancet Oncol
, vol.3
, pp. 529-36
-
-
Harries, M.1
Gore, M.2
-
2
-
-
0036714217
-
Part II: Chemotherapy for epithelial ovarian cancer-treatment of recurrent disease
-
Harries M Gore M. Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. Lancet Oncol 2002 3 537 45.
-
(2002)
Lancet Oncol
, vol.3
, pp. 537-45
-
-
Harries, M.1
Gore, M.2
-
3
-
-
0142053372
-
Current status of taxane and platinum-based chemotherapy in ovarian cancer
-
McGuire WP. Current status of taxane and platinum-based chemotherapy in ovarian cancer. J Clin Oncol 2003 21 Suppl. 10 133 5.
-
(2003)
J Clin Oncol
, vol.21
, Issue.10 SUPPL.
, pp. 133-5
-
-
McGuire, W.P.1
-
4
-
-
1542364058
-
Predicting the effectiveness of chemotherapy (Cx) in patients with recurrent ovarian cancer (ROC). a GINECO study [abstract]
-
Abstract 829
-
Pujade Lauraine E Paraiso D Curé H et al. Predicting the effectiveness of chemotherapy (Cx) in patients with recurrent ovarian cancer (ROC). A GINECO study [abstract]. Proc Am Soc Clin Oncol 2002 21 208a. Abstract 829.
-
(2002)
Proc Am Soc Clin Oncol
, vol.21
-
-
Pujade Lauraine, E.1
Paraiso, D.2
Curé, H.3
-
6
-
-
0242319868
-
Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma
-
A multicenter GINECO, phase II study
-
Guastalla JP Pujade Lauraine E Weber B et al. Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma. A multicenter GINECO, phase II study. Ann Oncol 1998 9 37 43.
-
(1998)
Ann Oncol
, vol.9
, pp. 37-43
-
-
Guastalla, J.P.1
Pujade Lauraine, E.2
Weber, B.3
-
7
-
-
0036499282
-
Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: Application toward a dynamic disease state model of ovarian cancer
-
Dizon DS Hensley ML Poynor EA et al. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. J Clin Oncol 2002 20 1238 47.
-
(2002)
J Clin Oncol
, vol.20
, pp. 1238-47
-
-
Dizon, D.S.1
Hensley, M.L.2
Poynor, E.A.3
-
8
-
-
1242342740
-
The role of anthracyclines in second-line therapy of ovarian cancer
-
Vermoken JB. The role of anthracyclines in second-line therapy of ovarian cancer. Int J Gynecol Cancer 2003 13 Suppl. 2 178 84.
-
(2003)
Int J Gynecol Cancer
, vol.13
, Issue.2 SUPPL.
, pp. 178-84
-
-
Vermoken, J.B.1
-
9
-
-
0024422604
-
Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: A GOG Study
-
Sutton GP Blessing JA Homesley HD et al. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a GOG Study. J Clin Oncol 1989 7 1672 6.
-
(1989)
J Clin Oncol
, vol.7
, pp. 1672-6
-
-
Sutton, G.P.1
Blessing, J.A.2
Homesley, H.D.3
-
10
-
-
0026599140
-
Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: Activity in platinum-resistant disease
-
Markman M Hakes T Reichman B et al. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 1992 10 243 8.
-
(1992)
J Clin Oncol
, vol.10
, pp. 243-8
-
-
Markman, M.1
Hakes, T.2
Reichman, B.3
-
11
-
-
0030525353
-
Ifosfamide seven-day infusion for recurrent and cisplatin refractory ovarian cancer
-
Dorval T Soussain C Beuzeboc P et al. Ifosfamide seven-day infusion for recurrent and cisplatin refractory ovarian cancer. J Infus Chemother 1996 6 47 9.
-
(1996)
J Infus Chemother
, vol.6
, pp. 47-9
-
-
Dorval, T.1
Soussain, C.2
Beuzeboc, P.3
-
12
-
-
0025346817
-
Ifosfamide given as 24 h infusion with mesna in patients with recurrent ovarian cancer: Preliminary results
-
Willemse PH van der Burg ME van der Gaast A et al. Ifosfamide given as 24 h infusion with mesna in patients with recurrent ovarian cancer: preliminary results. Cancer Chemother Pharmacol 1990 26 51 4.
-
(1990)
Cancer Chemother Pharmacol
, vol.26
, pp. 51-4
-
-
Willemse, P.H.1
Van Der Burg, M.E.2
Van Der Gaast, A.3
-
13
-
-
0000381874
-
Cyclophosphamide, adriamycin, cisplatin in recurrent platinum sensitive ovarian cancer: A randomised phase II study [abstract]
-
Abstract 751
-
Colombo N. Cyclophosphamide, adriamycin, cisplatin in recurrent platinum sensitive ovarian cancer: a randomised phase II study [abstract]. Proc Am Soc Clin Oncol 1996 15 279. Abstract 751.
-
(1996)
Proc Am Soc Clin Oncol
, vol.15
, pp. 279
-
-
Colombo, N.1
-
14
-
-
0003215792
-
A randomized study in recurrent ovarian cancer comparing the efficacy of single agent versus combination chemotherapy according to time to relapse [abstract]
-
Abstract 750
-
Bolis G Scarfone G Villa A et al. A randomized study in recurrent ovarian cancer comparing the efficacy of single agent versus combination chemotherapy according to time to relapse [abstract]. Proc Am Soc Clin Oncol 1996 15 279. Abstract 750.
-
(1996)
Proc Am Soc Clin Oncol
, vol.15
, pp. 279
-
-
Bolis, G.1
Scarfone, G.2
Villa, A.3
-
15
-
-
0036498921
-
Randomized controlled trial of single agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first line platinum based regimen
-
Cantu MG Buda A Parma G et al. Randomized controlled trial of single agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first line platinum based regimen. J Clin Oncol 2002 20 1232 7.
-
(2002)
J Clin Oncol
, vol.20
, pp. 1232-7
-
-
Cantu, M.G.1
Buda, A.2
Parma, G.3
-
16
-
-
0033976336
-
Ifosfamide-based drug combinations: Preclinical evaluation of drug interactions and translation into clinic
-
Vanhoefer U Schleucher N Klaassen U et al. Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into clinic. Semin Oncol 2000 27 8 13.
-
(2000)
Semin Oncol
, vol.27
, pp. 8-13
-
-
Vanhoefer, U.1
Schleucher, N.2
Klaassen, U.3
-
18
-
-
0029759230
-
Epirubicin and ifosfamide in metastatic breast cancer
-
Becher R Kloke O Hayungs J et al. Epirubicin and ifosfamide in metastatic breast cancer. Semin Oncol 1996 23 Suppl. 7 28 33.
-
(1996)
Semin Oncol
, vol.23
, Issue.7 SUPPL.
, pp. 28-33
-
-
Becher, R.1
Kloke, O.2
Hayungs, J.3
-
19
-
-
0025278347
-
Ifosfamide combination chemotherapy in advanced breast cancer
-
Schmid H Kaufman M Grischke EM et al. Ifosfamide combination chemotherapy in advanced breast cancer. Cancer Chemother Pharmacol 1990 26 Suppl S71 3.
-
(1990)
Cancer Chemother Pharmacol
, vol.26
, Issue.SUPPL.
, pp. 71-3
-
-
Schmid, H.1
Kaufman, M.2
Grischke, E.M.3
-
20
-
-
0028338769
-
Case report: Treatment of primary ovarian angiosarcoma with ifosfamide and doxorubicin
-
Cunningham MJ Brooks JS Noumoff JS. Case report: treatment of primary ovarian angiosarcoma with ifosfamide and doxorubicin. Gynecol Oncol 1994 53 265 8.
-
(1994)
Gynecol Oncol
, vol.53
, pp. 265-8
-
-
Cunningham, M.J.1
Brooks, J.S.2
Noumoff, J.S.3
-
21
-
-
0030017940
-
Salvage therapy with ifosfamide and mitoxantrone in advanced ovarian cancer
-
Marzola M Parma G Bonazzi C et al. Salvage therapy with ifosfamide and mitoxantrone in advanced ovarian cancer. Ann Oncol 1996 7 419 21.
-
(1996)
Ann Oncol
, vol.7
, pp. 419-21
-
-
Marzola, M.1
Parma, G.2
Bonazzi, C.3
-
22
-
-
0029893575
-
A combination of ifosfamide and mitoxantrone as salvage therapy in patients with advanced ovarian cancer
-
Nardi M Giulia MD Pollera CF et al. A combination of ifosfamide and mitoxantrone as salvage therapy in patients with advanced ovarian cancer. Cancer Chemother Pharmacol 1996 38 298 301.
-
(1996)
Cancer Chemother Pharmacol
, vol.38
, pp. 298-301
-
-
Nardi, M.1
Giulia, M.D.2
Pollera, C.F.3
-
23
-
-
0030039147
-
Defining progression of ovarian carcinoma during follow-up according to CA125: A North Thames Ovary Group study
-
Rustin GJ Nelstrop AE Tuxen MK et al. Defining progression of ovarian carcinoma during follow-up according to CA125: a North Thames Ovary Group study. Ann Oncol 1996 7 361 4.
-
(1996)
Ann Oncol
, vol.7
, pp. 361-4
-
-
Rustin, G.J.1
Nelstrop, A.E.2
Tuxen, M.K.3
-
24
-
-
0035879099
-
Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan
-
Gordon AN Fleagle JT Guthrie D et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001 15 3312 22.
-
(2001)
J Clin Oncol
, vol.15
, pp. 3312-22
-
-
Gordon, A.N.1
Fleagle, J.T.2
Guthrie, D.3
-
25
-
-
0030900145
-
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
-
ten Bokkel Huinink W Gore M Carmichael J et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997 15 2177 80.
-
(1997)
J Clin Oncol
, vol.15
, pp. 2177-80
-
-
Ten Bokkel Huinink, W.1
Gore, M.2
Carmichael, J.3
-
26
-
-
0024334410
-
The effect of ifosfamide and its metabolites on intracellular glutathione level in vitro and in vivo
-
Lind MJ McGown AT Hadfield JA et al. The effect of ifosfamide and its metabolites on intracellular glutathione level in vitro and in vivo. Biochem Pharmacol 1989 38 1835 40.
-
(1989)
Biochem Pharmacol
, vol.38
, pp. 1835-40
-
-
Lind, M.J.1
McGown, A.T.2
Hadfield, J.A.3
-
27
-
-
0025962117
-
Increased glutathione peroxidase activity in a human sarcoma cell line with doxorubicin resistance
-
Samuels BL Murray JL Cohen MB et al. Increased glutathione peroxidase activity in a human sarcoma cell line with doxorubicin resistance. Cancer Res 1991 51 521 7.
-
(1991)
Cancer Res
, vol.51
, pp. 521-7
-
-
Samuels, B.L.1
Murray, J.L.2
Cohen, M.B.3
-
28
-
-
0032144047
-
Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent
-
Markman M Kennedy A Sutton G et al. Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent. Gynecol Oncol 1998 70 272 4.
-
(1998)
Gynecol Oncol
, vol.70
, pp. 272-4
-
-
Markman, M.1
Kennedy, A.2
Sutton, G.3
-
29
-
-
0025194258
-
Epirubicin for pretreated advanced ovarian cancer
-
Coleman R Towlson K Wiltshaw E et al. Epirubicin for pretreated advanced ovarian cancer. Eur J Cancer 1990 26 850 1.
-
(1990)
Eur J Cancer
, vol.26
, pp. 850-1
-
-
Coleman, R.1
Towlson, K.2
Wiltshaw, E.3
-
30
-
-
0029950202
-
Phase II trial of epirubicin at standard dose in relapsed ovarian cancer
-
Palaez I Lacave AJ Palacio I et al. Phase II trial of epirubicin at standard dose in relapsed ovarian cancer. Eur J Cancer 1996 32A 899 900.
-
(1996)
Eur J Cancer
, vol.32
, pp. 899-900
-
-
Palaez, I.1
Lacave, A.J.2
Palacio, I.3
-
31
-
-
0036198668
-
Ifosfamide and Vinorelbine in advanced platinum-resistant ovarian cancer: Excessive toxicity with a potentially active regimen
-
Gonzalez-Martin A Crespo C Garcia-Lopez JL et al. Ifosfamide and Vinorelbine in advanced platinum-resistant ovarian cancer: excessive toxicity with a potentially active regimen. Gynecol Oncol 2002 84 368 73.
-
(2002)
Gynecol Oncol
, vol.84
, pp. 368-73
-
-
Gonzalez-Martin, A.1
Crespo, C.2
Garcia-Lopez, J.L.3
-
32
-
-
0026476151
-
The enigma of ifosfamide encephalopathy
-
Cerny T Kupfer A. The enigma of ifosfamide encephalopathy. Ann Oncol 1992 3 679 81.
-
(1992)
Ann Oncol
, vol.3
, pp. 679-81
-
-
Cerny, T.1
Kupfer, A.2
-
34
-
-
0025307207
-
Ifosfamide and mesna: Response and toxicity at standard and high dose schedules
-
Antman KH Elias A Ryan L. Ifosfamide and mesna: response and toxicity at standard and high dose schedules. Semin Oncol 1990 17 Suppl. 4 68 73.
-
(1990)
Semin Oncol
, vol.17
, Issue.4 SUPPL.
, pp. 68-73
-
-
Antman, K.H.1
Elias, A.2
Ryan, L.3
-
35
-
-
0035879099
-
Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan
-
Gordon AN Fleagle JT Guthrie D et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001 3312 22.
-
(2001)
J Clin Oncol
, pp. 3312-22
-
-
Gordon, A.N.1
Fleagle, J.T.2
Guthrie, D.3
-
36
-
-
0008810987
-
Pegylated liposomal doxorubicin (Caelyx) and ifosfamide (IFEX) in recurrent ovarian cancer (ROC): A phase I/II Gineco study [abstract]
-
Abstract 1577
-
Bourgeois H Curé H Guastalla JP et al. Pegylated liposomal doxorubicin (Caelyx) and ifosfamide (IFEX) in recurrent ovarian cancer (ROC): a phase I/II Gineco study [abstract]. Proc Am Soc Clin Oncol 2000 19 398a. Abstract 1577.
-
(2000)
Proc Am Soc Clin Oncol
, vol.19
-
-
Bourgeois, H.1
Curé, H.2
Guastalla, J.P.3
|